When a person arrives at their doctor's office having trouble thinking clearly or remembering things, one or a combination of several neurodegenerative diseases could be to blame. At this year's AAIC, ...

Summary These transgenic mice express a chimeric mouse/human APP carrying the Swedish mutation under the control of the mouse prion protein promoter. This line, C3-3, was generated in parallel with ...

Summary The endogenous APP gene was disrupted in these animals by homologous recombination. At birth, mice homozygous for the targeted allele are viable and do not display any gross physical or ...

With two amyloid immunotherapies in the clinic, it has become urgent to understand the factors that lead to ARIA, and how to avoid this sometimes-serious side effect. At the Alzheimer’s Association ...

Scientists offer new clues as to how overzealous neuronal firing may fuel synaptic loss in early Alzheimer's. In Science July 9, scientists led by Soyon Hong at University College London report that ...

Two new ApoE variants turned up in American populations. Protective variant W276C discourages ApoE from oligomerizing. Risk variant R189C promotes its lipidation. Lipidated ApoE4 disrupts microglial ...

Amyloid plaques drive the spread of tangles throughout a person’s brain, but much about this process remains mysterious. At this year’s AD/PD conference in Copenhagen, Denmark, speakers showed PET ...

Once more than 4 percent of tau molecules in a person’s blood are phosphorylated at residue 217, the clock starts ticking—toward the first symptoms of Alzheimer’s disease, that is. How long it might ...

Transferrin-receptor shuttles distribute antibody cargo throughout the parenchyma, steering clear of ARIA-provoking vascular amyloid. Trontinemab is enrolling Phase 3 for early AD, announces plans for ...

The MAPT haplotypes H1 and H2 are defined by a large inversion polymorphism on chromosome 17. The HI haplotype has been consistently linked to risk for several neurodegenerative diseases, particularly ...

Creating models for primary tauopathies sounds simple enough. Select a human tau gene variant that causes disease, stick it where the endogenous mouse gene sits in its genome, then wait a few months ...

At the 19th AD/PD conference, Alzforum reporters wrote 15 summaries of findings across both diseases. From a step toward finally having an α-synuclein PET tracer to a major focus on Trem2 as a drug ...